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Transplantation activity is increasing, leading to a growing 
number of patients at risk for toxoplasmosis. We reviewed 
toxoplasmosis prevention practices, prevalence, and 
outcomes for hematopoietic stem cell transplant (HSCT) 
and solid organ transplant (SOT; heart, kidney, or liver) 
patients in Europe. We collected electronic data on the 
transplant population and prevention guidelines/regula-
tions and clinical data on toxoplasmosis cases diagnosed 
during 2010–2014. Serologic pretransplant screening of 
allo-hematopoietic stem cell donors was performed in 80% 
of countries, screening of organ donors in 100%. SOT 
recipients were systematically screened in 6 countries. 
Targeted anti-Toxoplasma chemoprophylaxis was hetero-
geneous. A total of 87 toxoplasmosis cases were record-
ed (58 allo-HSCTs, 29 SOTs). The 6-month survival rate 
was lower among Toxoplasma-seropositive recipients and 
among allo-hematopoietic stem cell and liver recipients. 
Chemoprophylaxis improved outcomes for SOT recipients. 
Toxoplasmosis remains associated with high mortality 
rates among transplant recipients. Guidelines are urgently 
needed to standardize prophylactic regimens and optimize 
patient management.
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Toxoplasmosis is a zoonosis that infects humans and other warm-blooded animals worldwide; prevalence 
and clinical severity vary by geographic area (1). After 
primary infection, the parasite persists lifelong within dor-
mant tissue cysts. Transmission to humans mainly occurs 
by ingestion of food or water contaminated with oocysts 
from feces of infected felids or undercooked meat contain-
ing cysts (2). Although largely asymptomatic in adults, 
toxoplasmosis is a life-threatening opportunistic infection 
in immunocompromised patients of all ages. Similar to 
Pneumocystis pneumonia, toxoplasmosis has become more 
frequently diagnosed for patients receiving immunosup-
pressive therapy than for patients with HIV infection (3,4). 
The growing number of grafts makes transplant patients a 
population at increasing risk. In transplant recipients (solid 
organ transplant [SOT] or hematopoietic stem cell trans-
plant [HSCT]), disease can result from reactivation of past 
latent infection or from primary infection acquired through 
contaminated food or through a transplanted organ contain-
ing latent cysts (5). In contrast to incidence among HIV-
infected patients, the incidence of toxoplasmosis among 
transplant recipients is poorly documented; published stud-
ies reporting patient series are scarce (6–8), and the litera-
ture consists mostly of case reports (2,9–12). 
The risk for reactivation of chronic infection varies ac-
cording to the immunosuppressive protocol and therefore 
according to the type of graft (13); risk is highest for se-
ropositive allo-HSCT recipients receiving a seronegative 
graft. Among SOT recipients, the risk of a seronegative 
recipient (R–) acquiring infection from a seropositive do-
nor (D+) organ (D+/R–) depends on the organ type; risk is 
highest for heart transplant recipients. Prevention measures 
rely on pretransplant serologic screening of donor, recipi-
ent, or both and on chemoprophylaxis; however, guidelines 
and regulations differ largely among countries. Regarding 
chemoprophylaxis, a multicenter study in France revealed 
variable practices in terms of regimen and duration of treat-
ment (4). Some experts have proposed a tight clinical and 
molecular follow-up protocol for HSCT patients, aiming at 
early diagnosis of Toxoplasma reactivation to improve sur-
vival rates (14–16), but the cost:benefit ratio of this strategy 
is still under debate. We reviewed prevention practices im-
plemented in European countries and evaluated the burden 
of toxoplasmosis among HSCT and SOT recipients.
Methods
Participating Centers
We recruited applicants through 2 study groups of the 
European Society of Clinical Microbiology and Infec-
tious Diseases (ESCMID; the European Study Group on 
Clinical Parasitology and the European Study Group on 
Immunocompromised Hosts) and through the Spanish 
Transplantation Infection Study Group, the Italian Society 
of Clinical Microbiology Infections and Transplant Work-
ing Group, and the Swiss Transplant Cohort Study. For 
each country, a local coordinator was identified and was in 
charge of contacting investigators from transplantation or 
infectious diseases units from representative centers.
Data Collection
Participants were invited to answer a detailed questionnaire 
adapted to the type of graft and designed to collect the fol-
lowing information: Toxoplasma seroprevalence in the 
country (documented by articles or recent surveys); imple-
mentation of a case reporting system for toxoplasmosis in 
transplant recipients; annual number of transplant proce-
dures for each organ type in the participating center and in 
the whole country; pretransplant serologic screening policy 
for recipients and donors; implementation of recipient moni-
toring after transplantation and methods used (PCR, serol-
ogy); and chemoprophylaxis regimen and duration accord-
ing to organ type (if cotrimoxazole was given primarily for 
preventing Pneumocystis pneumonia, this use was recorded) 
and according to the recipient serologic results (primary 
or secondary prophylaxis, whether chemoprophylaxis was 
given to seronegative recipients, seropositive recipients, or 
both). When official national guidelines were lacking, to ob-
tain representative data, we collected information about local 
practices in several transplant centers whenever possible. 
As a second step, we sent an electronic case report-
ing form to all voluntary participating centers, which retro-
spectively recorded the number of cases of toxoplasmosis 
diagnosed per center over a 5-year period (2010–2014). 
The form collected the following information: patient age 
and sex; date of transplantation and type of graft; Toxo-
plasma serologic status of recipient and donor; date of 
toxoplasmosis diagnosis; site of infection (cerebral, ocular, 
disseminated); tools contributing to diagnosis (serology, 
molecular diagnosis, pathology, direct examination, imag-
ing); chemoprophylaxis type, date of initiation, and dura-
tion; patient survival at 2 and 6 months; and date of death, 
if applicable. From each center and for each organ type, we 
also collected the mean patient age and the mean percent-
age of the whole transplant patient population surviving at 
2 months and at 6 months. The number of cases and clini-
cal data were retrieved from hospital medical or laboratory 
databases or from local or national databases, if existing. 
Participants were invited to send only aggregated data gen-
erated automatically by the database. The study was ap-
proved by the Ethics Committee of the University Hospital 
of Rennes, France (approval no. 15.12).
Statistical Analyses
Descriptive statistics are expressed as frequency (percent-
age) or mean ± SE. Comparison of qualitative data between 
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groups was based on exact χ2 tests for equal proportions 
or Fisher exact tests if single table values were <5; quan-
titative data were compared by using analysis of variance 
or t-test (nonparametric test). We computed data by using 
SAS software version 9.4 (SAS Institute, Cary, NC, USA).
Results
Participating Centers, Transplantation Activity,  
and Case Notification 
Overall, 46 centers from 11 countries (1–10 centers/coun-
try) participated in the survey; countries represented were 
France, Germany, Greece, Italy, Romania, Serbia, Slova-
kia, Spain, Switzerland, Turkey, and the United Kingdom 
(online Technical Appendix, https://wwwnc.cdc.gov/EID/
article/24/8/18-0045-Techapp1.pdf). Responses indicated 
that 5 countries (Switzerland, Slovakia, Turkey, Greece 
and the United Kingdom) report toxoplasmosis cases in a 
national database.
During 2010–2014, the mean annual number (range) 
of allo-HSCT procedures reported per country was 1,016 
(13–1,900) and of auto-HSCT was 1,524 (14–3,078) (on-
line Technical Appendix). Regarding SOT recipients, the 
mean annual number (range) of transplantations was 155 
(10–420) for heart, 1,286 (55–3,074) for kidney, and 622 
(35–1,241) for liver. The cumulative annual transplant 
activity among the responding centers reached a total of 
1,089 allo-HSCT and 1,168 auto-HSCT (26 centers) and, 
for SOT, 394 heart (26 centers), 2,566 kidney (35 centers), 
and 1,455 liver (26 centers) transplants.
Pretransplant Serologic Screening for Toxoplasmosis
Although serologic screening of HSCT donors is not manda-
tory, all responding countries reported that they were per-
forming this screening. Screening of allo-HSCT recipients 
was performed in all countries except Slovakia (mandatory in 
4 countries), whereas screening of auto-HSCT recipients was 
performed regularly (4 countries), inconstantly (5 countries), 
or not at all (1 country). Overall, of 26 responding centers, 
24 centers screened allo-HSCT and 17 screened auto-HSCT 
recipients for Toxoplasma antibodies before transplantation.
Serologic screening of solid organ donors (heart, kid-
ney, or liver) was performed in all countries, although 
screening was reportedly mandatory in only 7 countries 
(France, Greece, Italy, Romania, Slovakia, Switzer-
land, and Turkey). At most centers, SOT recipients were 
screened (24/26 liver, 31/35 kidney, and 25/26 heart).
Anti-Toxoplasma Chemoprophylaxis Practices  
and Follow-up
Virtually all allo-HSCT recipients received cotrimoxazole 
chemoprophylaxis, whether primarily targeting Pneu-
mocystis or Toxoplasma. At the 24 responding centers, 
cotrimoxazole was usually prescribed for >6 months de-
spite the lack of official guidelines at 11 (46%) centers. The 
preferred regimen at 60% of centers was 960 mg 3 times 
a week but ranged from 480 mg 2 times a week to 1,920 
mg 3 times a week. Auto-HSCT patients at 73% of cen-
ters received cotrimoxazole, administered mostly for 3 or 6 
months. Serologic follow-up was reported by 2 allo-HSCT 
centers and PCR-based follow-up by 4.
For heart transplant recipients, 24 (92%) of 26 centers 
stated that they gave cotrimoxazole prophylaxis (3 months 
to lifelong), and 10 (43%) of 23 centers implemented sero-
logic follow-up for Toxoplasma 2 and 4 times per year, par-
ticularly in cases of serologic mismatch (D+/R–). The most 
frequently prescribed regimen was 960 mg of cotrimoxa-
zole 3 times a week or 480 mg daily. Although anti-Pneu-
mocystis prophylaxis was implemented at 29 (83%) of 35 
kidney and 17 (65%) of 26 liver transplant centers for 3–12 
months, specific recommendations regarding toxoplas-
mosis chemoprophylaxis in this population were reported 
by only 4 countries (France, Greece, Spain, Turkey). The 
most frequently used regimen was cotrimoxazole at 480 mg 
daily (50% of kidney and 40% of liver transplant centers). 
Serologic monitoring of D+/R– patients was reportedly 
performed at 6 kidney and 5 liver transplant centers.
Incidence and Clinical Presentation of Toxoplasmosis
Overall, during the 5-year study period, 87 cases of Toxo-
plasma infection in transplant patients (58 HSCT, 29 SOT) 
were reported from 15 centers in 8 countries (online Tech-
nical Appendix). Severe manifestations (cerebral toxoplas-
mosis, disseminated toxoplasmosis, pulmonary toxoplas-
mosis) were more frequently observed (42 [48%] patients) 
than were mild manifestations (ocular toxoplasmosis, fe-
ver; 14 [16%] patients). A total of 31 (36%) patients had no 
apparent clinical signs. Asymptomatic episodes occurred 
mainly among HSCT recipients (81%) and were diagnosed 
mostly on the basis of a positive PCR (84%). Symptom-
atic HSCT recipients most often had disseminated (10/33, 
30%) or cerebral (11/33, 33%) toxoplasmosis; these cases 
accounted for 60% of all cases of disseminated and 85% of 
cerebral toxoplasmosis (Table 1).
For the 87 reported cases, PCR was the most helpful 
diagnostic tool (77 [89%] cases), followed by imaging (32 
[37%] cases) and serology (28 [32%] cases) (Table 1). PCR 
was reportedly positive for 100% of patients with cerebral 
and 90% with pulmonary toxoplasmosis (Table 1).
Pretransplantation Toxoplasma serologic test results 
for donor and recipient were available for 70 of the 87 pa-
tients (46 HSCT and 24 SOT). Toxoplasmosis occurred in 
the main groups at risk: in 35 (76%) of 46 D–/R+ HSCT re-
cipients and 11 (46%) of 24 D+/R– SOT recipients (Table 
2). Overall, 35 patients (18 HSCT and 17 SOT recipients) 
received chemoprophylaxis (Table 3). Only 4 (36%) of 11 
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D+/R– SOT recipients received chemoprophylaxis, but for 
all of them toxoplasmosis occurred after discontinuation of 
prophylaxis (data not shown). Overall, toxoplasmosis was 
diagnosed after the end of prophylaxis for 17 recipients 
(9 HSCT and 8 SOT). For 9 HSCT and 5 SOT recipients, 
toxoplasmosis occurred during chemoprophylaxis (Table 
3). Of these, 13 (93%) were asymptomatic: 1 kidney, 1 
heart, and 11 HSC transplant recipients (Table 1). The pro-
portion of mismatched cases (D+/R–) did not differ accord-
ing to organ type (Table 4).
The mean time between transplantation and toxoplas-
mosis diagnosis was shorter among patients with pulmo-
nary toxoplasmosis (p<0.05) (Table 1) than among patients 
with other types of disease manifestation. For seropositive 
recipients, the mean time to toxoplasmosis onset was short 
(<4 months after transplantation) compared with that for 
seronegative recipients (>4 years) (Table 2). Furthermore, 
the time to disease onset after transplantation was shorter 
among HSCT patients than SOT recipients (p<0.0001) (Ta-
ble 4). The incidence of toxoplasmosis differed among the 
responding countries but seemed to not be linked to the se-
roprevalence in the country (online Technical Appendix).
Risk Factors for Death 
Survival rates differed significantly between HSCT and 
SOT recipients (p<0.001) (Table 5). The 2-month surviv-
al rate was significantly poorer for patients with cerebral 
(38%) or pulmonary (50%) toxoplasmosis (p<0.001) (Ta-
ble 1). Survival rates were also poorer for seropositive pa-
tients (p<0.05 at 2 months and p<0.001 at 6 months) (Table 
5), mainly consisting of HSCT patients (Table 2). Of note, 
the percentage of asymptomatic patients who survived 6 
months (58%) was similar to that of patients with pulmo-
nary (50%) or disseminated (53%) toxoplasmosis (Table 
1). A lower percentage of HSCT and liver transplant re-
cipients survived at 2 and 6 months after diagnosis; deep 
site–associated toxoplasmosis was diagnosed for only half 
of them (Table 4). The survival rates for HSCT (38%) and 
liver transplant (50%) recipients with toxoplasmosis were 
significantly lower than those for the general HSC (84%) 
and liver transplant (75%) populations (p<0.05) (Table 4).
Transplant recipients in whom toxoplasmosis devel-
oped were less likely to survive if they were not receiving 
chemoprophylaxis before or at onset of disease (p<0.05 at 2 
months and p<0.01 at 6 months after disease onset) (Table 
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Table 1. Characteristics of 87 transplant patients with toxoplasmosis, according to clinical presentation, Europe, 2010–2014* 
Variables 
Clinical type 
p value Cerebral Ocular Disseminated Pulmonary Fever alone No signs 
No. (%) patients 13 (15) 4 (5) 19 (22) 10 (11) 10 (11) 31 (36)  
Patient age, y, mean  SE 37.0  7.7 60.7  0.8 47.8  5.6 53.1  4.8 35.5 4.4 46.4  4.2 <0.0001 
Time graft/diagnosis, wk, mean  SE 123 ± 151 313 ± 175 163 ± 124 19 ± 11 73 ± 43 99 ± 51 <0.05  
Diagnosis by, no. (%)        
 PCR 13 (100) 3 (75) 17 (89) 9 (90) 9 (90) 26 (84) <0.001 
 Serology 3 (23) 3 (75) 9 (47) 2 (20) 5 (50) 5 (16) 0.2278 
 Imaging 12 (92) 3 (75) 8 (42) 7 (70) 0 2 (6) <0.01  
 Microscopy 1 (8) 0 6 (32) 1 (10) 0 0 <0.01  
Graft type, no. (%)       <0.05  
 Liver, n = 8 1 (8) 1 (25) 3 (16) 2 (20) 0 1 (3)  
 Kidney, n = 9 1 (8) 1 (25) 1 (5) 2 (20) 3 (30) 1 (3)†  
 Heart, n = 12 0 1 (25) 5 (26) 0 2 (20) 4 (13)‡  
 Allo-HSC, n = 58 11 (85) 1 (25) 10 (53) 6 (60) 5 (50) 25 (81)§  
No. with mismatch, n = 11 0 1 (25) 5 (26) 1 (10) 4 (40) 0 <0.05  
Survival, no. (%)        
 2 mo 5 (38) 4 (100) 13 (68) 5 (50) 10 (100) 24 (77) <0.0001 
 6 mo 2 (15) 4 (100) 10 (53) 5 (50) 7 (70) 18 (58) <0.001 
*HSC, hematopoietic stem cell. 
†This patient was receiving chemoprophylaxis. 
‡1 patient was receiving chemoprophylaxis.  
§11 patients were receiving chemoprophylaxis. 
 
 
Table 2. Characteristics of transplant donors and recipients at transplantation, according to Toxoplasma serologic status, Europe, 
2010–2014* 
Serologic status of 
donor/recipient† 
Prophylaxis,  
no. (%) 
Graft type, no. Survived 6 mo, 
no. (%) 
Wks between diagnosis 
and graft, mean  SE Liver Kidney Heart HSC 
Positive/positive, n = 9‡ 5 (56) 2 0 1 6 3 (33) 21  9 
Positive/negative, n = 11§ 4 (36) 3 4 4 0 9 (82) 309  275 
Negative/positive, n = 36¶ 12 (33) 0 0 1 35 12 (33) 15  3 
Negative/negative, n = 14 9 (64) 2 2 5 5 11 (79) 123  31 
p value 0.1975 NA NA NA NA <0.01 (0.0029) <0.05 
*HSC, hematopoietic stem cell; NA, not applicable. 
†Missing data for 17 patients.  
‡2 liver transplant recipients died.  
§Group in which solid organ transplant patients are most at risk for toxoplasmosis.  
¶Group in which HSC transplant patients are most at risk for toxoplasmosis. 
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5); this finding was particularly common among SOT re-
cipients (p<0.05) (Table 3). However, despite chemopro-
phylaxis, the outcome remained poorer for HSCT patients 
than for SOT patients (Tables 3, 5).
Discussion
We provide an overview of practices used to prevent 
toxoplasmosis in transplant patients in Europe. Despite 
the well-recognized risk linked to either endogenous re-
activation or to transplantation of a cyst-containing organ, 
prevention policies seem heterogeneous among countries. 
Serologic screening of solid organ or hematopoietic stem 
cell donors for Toxoplasma, although not mandatory in 
all countries, seems to be general practice, probably as a 
result of recommendations of national societies of trans-
plantation, and is mandatory when organs are exchanged 
between countries. Similarly, pretransplant serologic 
screening of recipients, although also not mandatory in all 
countries, was reportedly performed by nearly all respond-
ing centers. However, for 17 cases, the serologic status of 
the recipient or donor was not available in medical charts. 
Management practices regarding chemoprophylaxis based 
on donor and recipient serologic results vary substantially, 
particularly for kidney and liver transplant patients. In-
deed, only 35 (50%) of 70 recipients had received che-
moprophylaxis, although it was indicated either because 
of Toxoplasma mismatch (SOT) or seropositivity (HSCT). 
Only 4 (36%) of 11 SOT patients with D+/R– serologic 
results had received chemoprophylaxis. These 4 patients 
were all alive 6 months after transplantation. However, our 
study did not address long-term survival, which at 5 years 
after transplantation was reportedly poorer for D+/R– than 
for D–/R– heart transplant recipients (17). In that study, 
Chehrazi-Raffle et al. (17) did not record the duration of 
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Table 3. Toxoplasmosis occurrence and outcomes for HSCT and SOT patients, according to prophylaxis, Europe, 2010–2014* 
Characteristic HSCT, no. (%), n = 58† SOT, no. (%), n = 29‡ p value 
Seropositive before transplantation 41/46 (89)§ 4/24 (17)¶ <0.0001 
Diagnosis during chemoprophylaxis 9/50 (18) 5/28 (18) NS 
Diagnosis after chemoprophylaxis 9/50 (18) 8/28 (29) NS 
2-mo survival rate    
 With prophylaxis 13/18 (72) 17/17 (100) <0.05 
 Without prophylaxis 18/32 (56) 9/11 (82) 0.1657 
6-mo survival rate    
 With prophylaxis 9/18 (50) 17/17 (100) 0.01 
 Without prophylaxis 9/32 (28) 7/11 (64)# 0.0679 
*HSCT, hematopoietic stem cell transplant; NS, not significant; SOT, solid organ transplant. 
†Prophylaxiis data missing for 8 patients. 
‡Prophylaxis data missing for 1 patient; incomplete information regarding dates of onset and/or stop of cotrimoxazole for 4 patients. 
§Serology data missing data for 4 patients.  
¶Serology data missing data for 4 patients.  
#p<0.05 between SOT with or without chemoprophylaxis. 
 
 
Table 4. Characteristics of transplant patients with toxoplasmosis, according to graft type and comparison to overall graft population, 
Europe, 2010–2014* 
Characteristics 
Allo-HSC 
 
Kidney 
 
Liver 
 
Heart 
p value 
Case-
patients All TP 
Case-
patients All TP 
Case-
patients All TP 
Case-
patients All TP 
Patients, no.  58 4,108  9 6,507  8 2,983  12 998 NA 
Age, y, mean  SE 46.8 ± 5.3 50.7  44.6  5.9 50.9  55.1  1.5 51.6  44.4  6.4 47.5 NA 
Female sex, % 43 38  44 63  38 30  17 22 NA 
Male sex, % 57 62  56 37  62 70  83 78 NA 
Mean time diagnosis/graft, 
wk, mean  SE 
20.6  4.6 NA  198  68 ND  152  144 ND  441  155 ND <0.0001 
Mean time diagnosis/death, 
d, mean  SE 
47  18 NA  33 ND  38  17 ND  NA ND 0.8595 
Mismatched serologic results 
(D+/R–), no. (%) 
0 NA  4 (33) NA  3 (38) NA  4 (33) NA 0.8923 
2-mo survival, no. (%) 36 (62) ND  8 (89) ND  5 (63) ND  12 (100) ND <0.05 
Deep site involvement 12 (43) ND  3 (60) ND  4 (57) ND  6 (100) ND 0.0513 
Fever only  5 (100) ND  3 (100) ND  0 ND  2 (100) ND 1 
No clinical signs 18 (72)   1 (100)   1 (100)   4 (100)  0.1407 
6-mo survival, %† 38 84‡  89 72  50 75§  100 60 <0.0001 
 Deep site involvement 25 NA  60 NA  28 NA  100 NA <0.01 
 Fever only  40 NA  100 NA  0 NA  100 NA 0.2083 
*D+, donor positive; NA, not applicable; ND, not determined; NS, not significant; R–, recipient negative; TP, transplant patients. 
†The survival rate for the general TP population was calculated at a time similar to the mean time of diagnosis of toxoplasmosis after graft in case-
patients. 
‡p<0.01 compared with case-patients.  
§p<0.05 compared with case-patients.  
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chemoprophylaxis, a parameter that could be of greater 
interest. Similarly, only 18 HSCT patients received che-
moprophylaxis, although 45 were known to be seroposi-
tive (Table 3). Our study also did not address long-term 
disabilities resulting from toxoplasmosis.
Even with this limited number of cases reported by 
the participating centers, our study provides some helpful 
insights and useful data. From a diagnosis point of view, 
our findings confirm that PCR has become an essential 
microbiological tool for investigating active infection, as 
already emphasized in previous studies (18,19). Indeed, we 
can confirm that 9 (10.3%) of the 87 cases of toxoplasmosis 
were diagnosed by PCR in patients with fever only; thus, 
earlier treatment could be commenced before more seri-
ous complications developed; these patients were mostly 
HSCT recipients. PCRs on blood from 26 patients with no 
obvious clinical signs were also positive. This finding is 
consistent with previously reported findings for allo-HSCT 
patients in centers where routine monitoring by PCR of 
blood is conducted for several months after transplantation 
(14–16,20,21). Martino et al. (22) concluded that clinical 
toxoplasmosis evolved in about one third of these patients 
and that early treatment increased survival rates. In our 
study, survival rates were poor among patients who were 
asymptomatic at the time of diagnosis (58%) (Table 1), 
probably because as allo-HSCT patients they were at high 
risk for death from other causes. Our study did not record 
what treatment decisions were taken as a direct result of 
PCR results, and so a more detailed future study of treat-
ment regimens and how quickly they were initiated may 
provide further valuable insights into factors affecting mor-
tality rates in this clinical group.
Not surprisingly, among the 87 patients, the propor-
tion with disseminated and pulmonary toxoplasmosis was 
high; this clinical picture is known to be frequent among 
transplant patients (4,23,24). The high frequency (100%) 
of positive PCR results among patients with cerebral toxo-
plasmosis differs from previous estimates of sensitivity in 
this clinical setting (2), suggesting high circulating parasite 
loads, late diagnoses, or both, which could account for the 
unusually high mortality rate (85%) among patients with 
cerebral toxoplasmosis in this study. Another explanation 
is that diagnostic sensitivity of molecular diagnosis has 
been mainly evaluated in HIV-infected patients, a patient 
population that differs from transplant recipients and expe-
riences more severe disease with rapid dissemination of the 
parasites. On the other hand, ocular toxoplasmosis, a mild 
form of the disease, occurred mostly after the first year after 
transplantation, when immune suppressive therapy is usu-
ally reduced, thus explaining the 100% survival rate, prob-
ably resulting from confinement of parasites in the ocular 
compartment (25).
In HSCT patients, Toxoplasma reactivation predomi-
nantly occurred within several months (20.6 ± 4.6 weeks) 
after engraftment, which might suggest that chemoprophy-
laxis was stopped too early. Indeed, toxoplasmosis was 
diagnosed for 9 HSCT patients after chemoprophylaxis 
was stopped (Table 3); this finding is consistent with the 
policy at 9 centers of discontinuing chemoprophylaxis at 
6 months. These data support the practice of monitoring 
CD4+ T-cell counts to guide chemoprophylaxis discontinu-
ation, as suggested by others (13). However, toxoplasmosis 
was also diagnosed during chemoprophylaxis for 9 addi-
tional HSCT and 5 SOT patients, which might be related to 
inadequate regimens of cotrimoxazole or poor observance. 
A recent systematic review (13) reported that breakthrough 
toxoplasmosis in HSCT patients was observed when cotri-
moxazole was given only 2 times per week at a dosage of 
960 mg (57% of cases) or 480 mg daily (18%).
A major finding of this study is the observation that 
life-threatening toxoplasmosis can occur in HSCT and 
SOT patients after chemoprophylaxis is stopped. However, 
in SOT patients, the rather late occurrence after transplant 
(>3 years) and the high survival rates suggest that infec-
tion acquired long after transplantation is usually mild and 
the source is probably contaminated food. Conversely, 
life-threatening early infection was associated with a high 
mortality rate and was mostly observed in liver transplant 
patients, suggesting that serologic results might not have 
been taken into account to guide chemoprophylaxis.
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Table 5. Survival among transplant patients with toxoplasmosis, according to patients’ characteristics, Europe, 2010–2014 
 
Characteristic 
2-mo survival 
 
6-mo survival 
No. patients/no. 
survived (%)  p value* 
No. patients/no. 
survived (%) p value* 
All patients 61/87 (70) Not applicable  46/87 (53) Not applicable 
Chemoprophylaxis      
 Yes 30/35 (86) <0.05  26/35 (74) <0.01 
 No 27/43 (63)   16/43 (37)  
Recipient serologic status      
 Positive 27/45 (60) <0.05  15/45 (33) <0.001 
 Negative 22/25 (88)   20/25 (80)  
Type of graft      
 Hematopoietic stem cell 36/58 (62) <0.05  22/58 (38) <0.001 
 Solid organ  25/29 (86)   24/29 (83)  
*Exact 2 test. 
 
Toxoplasmosis in Transplant Recipients, Europe
Overall, prognosis of Toxoplasma infection was good 
for SOT patients; the all-cause mortality rate of 17% was 
similar to that reported from Spain (13.6%), where 17 of 22 
patients had a primary-acquired infection (6). Higher prev-
alence and severity of disease was confirmed among HSCT 
patients; survival rate was only 38% at 6 months, similar 
to mean survival rates recently reported (13). We assume 
that death was attributable to toxoplasmosis in deceased 
HSCT and liver transplant patients because their 6-month 
survival rate was significantly poorer than that of their 
counterparts without toxoplasmosis (p<0.01). A similar 
effect of toxoplasmosis on survival of HSCT patients has 
been recently demonstrated in a case–control study (26). 
However, whether chemoprophylaxis positively influences 
outcome remains unclear. Indeed, overall survival rates 
were better among patients who received cotrimoxazole 
than among those who received no treatment; but when 
considering HSCT and SOT patients separately, survival 
rates remained significantly better for SOT patients only. 
This finding raises the question of the effectiveness of pro-
phylaxis, in terms of regimen and duration.
This study has several limitations. First, we used ag-
gregated data, so individual analyses or modifications of 
the analysis plan were not possible after data collection. 
Therefore, individual data such as immunosuppressive 
regimen, graft versus host disease, or simultaneous infec-
tions were not recorded, and multivariate analyses to fur-
ther explore mortality rates were not possible. The number 
of participating centers per country varied, and for some 
countries (particularly Germany and Turkey), these centers 
accounted for a small proportion of the transplantation ac-
tivity in the whole country (online Technical Appendix); 
thus, we cannot be sure that the data collected were repre-
sentative for the whole country. The absence of correlation 
between seroprevalence and the number of cases reported 
among countries may be attributed to several confound-
ing factors, such as 1) good management of prevention in 
countries where seroprevalence is high, 2) lack of aware-
ness and possible underdiagnosis of Toxoplasma-associat-
ed risk in countries where seroprevalence or transplanta-
tion activity is low, 3) underreporting because of lack of 
follow-up, 4) overdiagnosis because of systematic screen-
ing (asymptomatic cases), or 5) migration of patients from 
eastern Europe (higher seroprevalence) to western Europe 
for transplantation (27).
Overall, this study confirms that toxoplasmosis in 
transplant recipients is a clinical problem throughout Eu-
rope, regardless of local seroprevalence. This finding sug-
gests that substantial health gains may be achieved by the 
development and adoption of common prevention guide-
lines based on best practice. Whether chemoprophylaxis 
duration should be extended and for what duration remains 
to be determined. Nevertheless, our results suggest that to 
prevent late onset of toxoplasmosis, cotrimoxazole should 
be given for >6 months. In case of drug intolerance, low 
dosage, or discontinuation, follow-up by regular PCR of 
blood could help guide preemptive treatment. In SOT pa-
tients with Toxoplasma mismatch (D+/R–), cotrimoxazole 
prophylaxis should be given for >1 year. Last, recommen-
dations associated with hygiene, similar to those provided 
to seronegative pregnant women to avoid contamination, 
should be extended to all seronegative transplant patients.
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